NeuBase approves $0.13/share initial distribution in liquidation; CEO/CFO resigns, board change

NeuBase Therapeutics, Inc.

Todd Branning resigns as Interim CEO and CFO effective Jan 3, 2025; appointed to Board on Jan 4.
Dov Goldstein resigns from Board effective immediately on Jan 4, 2025.
Board approved Plan of Distribution: initial distribution of ~$500,000 ($0.13 per share) to stockholders of record June 26, 2024.
Company is in process of dissolution; shares delisted from Nasdaq in May 2024.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Todd P. Branning

Director

NeuBase Therapeutics, Inc.

Effective: 2025-01-04
Filed: January 7, 2025, 6:59 PM ET

On January 4, 2025, Mr. Branning was appointed to the Board of Directors of the Company (the “Board”).

Departed (interim)

Todd P. Branning

Interim Chief Executive Officer and Chief Financial Officer

NeuBase Therapeutics, Inc.

Effective: 2025-01-03
Filed: January 7, 2025, 6:59 PM ET

Todd P. Branning, the Interim Chief Executive Officer and Chief Financial Officer of NeuBase Therapeutics, Inc. (the “Company”), notified the Company of his resignation as interim Chief Executive Officer and Chief Financial Officer, effective as of close of business on January 3, 2025.

Departed

Dov A. Goldstein

Director

NeuBase Therapeutics, Inc.

Effective: 2025-01-04
Filed: January 7, 2025, 6:59 PM ET

On January 4, 2025, Dov A. Goldstein, M.D. notified the Company of his resignation as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Todd P. Branning was appointed as Director at NeuBase Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 4, 2025, Mr. Branning was appointed to the Board of Directors of the Company (the “Board”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Todd P. Branning resigned as Interim Chief Executive Officer and Chief Financial Officer at NeuBase Therapeutics, Inc..

Action: resigned
Role: Interim Chief Executive Officer and Chief Financial Officer

Exact text from the filing

Todd P. Branning, the Interim Chief Executive Officer and Chief Financial Officer of NeuBase Therapeutics, Inc. (the “Company”), notified the Company of his resignation as interim Chief Executive Officer and Chief Financial Officer, effective as of close of business on January 3, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dov A. Goldstein resigned as Director at NeuBase Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On January 4, 2025, Dov A. Goldstein, M.D. notified the Company of his resignation as a member of the Board, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-25-001664

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.